News

Opioid maker Insys to pay $225M to settle fraud charges

Wednesday's settlement follows last month's conviction of five former Insys executives, including the company's founder John Kapoor, for their involvement in bribing physicians to...

From BIO meeting, Merck CEO backs capitalism, rebuts industry’s critics

In an era of criticism and scrutiny for biopharma companies, executives gathered at the 2019 BIO meeting have debated how the industry can push...

3 takeaways from cancer’s biggest conference

The cancer field's largest conference has come and gone, and with it a window into the thousands of clinical trials being run in hopes...

Don’t worry about Humira biosimilars, the pipeline will deliver, AbbVie says

As Humira (adalimiumab) goes, so goes AbbVie. And it may require quite a few new products to replace the rheumatoid arthritis giant, which earned...

Gilead to build manufacturing site in Maryland to boost cell therapy

The new facility should help the big biotech meet some of the unique challenges of manufacturing CAR-T therapies. The process is complex and time...

Sarepta may have seen off another rival in Wave

Wave Life Sciences has joined the biopharma sector's gold rush to treat DMD, a genetic disorder that causes progressive musculoskeletal disability in boys. So far,...

Audentes lays down marker in muscular dystrophy

Audentes Therapeutics is trying to show Sarepta isn't the only game in town when it comes to DMD. The collaboration with Nationwide's Children Hospital...

J&J invests in integrin therapies via Morphic deal

Four months after Morphic reached an R&D deal with AbbVie, the Waltham, Massachusetts-based biotech has found another drugmaking giant to partner with. Morphic and AbbVie...

In R&D, small biotechs hold their own against big pharma

Despite spending billions on R&D, big pharma doesn't punch its weight in discovering the new molecules that eventually make it to market. Instead, it's...

Takeda takes another step into cell therapy research

Takeda, on the cusp of closing its deal to acquire Shire, is also working to ramp up its efforts in emerging fields of cancer...

Latest articles

CMS chief declines to provide details on Trump healthcare...

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments...

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 

Subscribe to our newsletter